| Date | Title | Description |
| 15.07.2026 | Blow-fill-seal Technology Market Forecast Signals Strong Demand for Integrated Aseptic Manufacturing | The Blow-fill-seal Technology Market size was valued at USD 386.34 Million in 2025 and the total Blow-fill-seal Technology revenue is expected to grow at a CAGR of 5.37% from 2026 to 2032, reaching nearly USD 557.18 Million.
Blow-fill-seal ... |
| 08.07.2026 | Loomis appoints Tobias Hägglöv as Chief Financial Officer | Loomis appoints Tobias Hägglöv as Chief Financial Officer
Wed, Jul 08, 2026 15:00 CET Report this content
Loomis AB has appointed Tobias Hägglöv as Chief Financial Officer (CFO) and member of Group Management. He will assume the position on... |
| 15.06.2026 | Recipharm expands US sterile fill and finish capabilities to support growing demand for biologics and advanced therapies | Recipharm expands US sterile fill and finish capabilities to support growing demand for biologics and advanced therapies
Mon, Jun 15, 2026 14:01 CET Report this content
Major investment expands Recipharm’s US sterile manufacturing footprint... |
| 08.06.2026 | Recipharm and Fusix Biotech advance novel oncolytic virus platform | Recipharm and Fusix Biotech advance novel oncolytic virus platform
Mon, Jun 08, 2026 11:51 CET Report this content
Collaboration to advance novel oncolytic virus-based cancer immunotherapies
Recipharm to support development and GMP manufact... |
| 28.05.2026 | Recipharm boosts BFS capacity with strategic manufacturing investment | Recipharm boosts BFS capacity with strategic manufacturing investment
Thu, May 28, 2026 11:21 CET Report this content
New BFS line adds significant sterile manufacturing capacity to support growing customer demand
With 50 years of BFS exper... |
| 16.04.2026 | CEPI awards seed funding to Analysis Zero to advance real-time RNA vaccine quality testing using NMR technology | CEPI awards seed funding to Analysis Zero to advance real-time RNA vaccine quality testing using NMR technology
Thu, Apr 16, 2026 10:00 CET Report this content
CEPI funds Analysis Zero, a Recipharm company, to explore real-time RNA vaccine ... |
| 08.04.2026 | Recipharm reports strong 2025 sustainability performance, advancing industry leadership | Recipharm reports strong 2025 sustainability performance, advancing industry leadership
Wed, Apr 08, 2026 10:00 CET Report this content
B rating for Climate Change, A- for Water Security and A for Supplier Engagement Assessment from CDP
20%... |
| 02.03.2026 | Recipharm Advanced Bio to deliver series of seminar to U.S. FDA showcasing novel PAT and digital infrastructure to enable real-time testing and continuous biomanufacturing | Recipharm Advanced Bio to deliver series of seminar to U.S. FDA showcasing novel PAT and digital infrastructure to enable real-time testing and continuous biomanufacturing
Mon, Mar 02, 2026 10:24 CET Report this content
Mobilised “lab on wh... |
| 19.02.2026 | Recipharm strengthens high potency capabilities with new pilot and development investment | Recipharm strengthens high potency capabilities with new pilot and development investment
Thu, Feb 19, 2026 09:00 CET Report this content
Investment in new high potency GMP pilot scale capabilities at Leganés, Spain, strengthening support f... |
| 26.01.2026 | Recipharm expands manufacturing to meet demanding FDA requirements | Recipharm expands manufacturing to meet demanding FDA requirements
Mon, Jan 26, 2026 09:00 CET Report this content
Established a new, dedicated non-bacterial beta-lactam manufacturing facility in response to FDA guidance
Secured a strategic... |
| 01.12.2025 | Infant Bacterial Therapeutics AB secures partnership with Recipharm Advanced Bio for commercial production of drug substance | Infant Bacterial Therapeutics AB secures partnership with Recipharm Advanced Bio for commercial production of drug substance
Mon, Dec 01, 2025 08:00 CET Report this content
IBP-9414 targets mortality and gastrointestinal injury in premature... |
| 26.11.2025 | Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support | Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support
Wed, Nov 26, 2025 09:00 CET Report this content
Telomir-1 has now entered GMP preparation, and Ketamir-2 has completed the Phase 1 SAD stage,... |
| 28.10.2025 | Recipharm secures major additional grant to develop AI-enabled manufacturing technologies | Recipharm secures major additional grant to develop AI-enabled manufacturing technologies
Tue, Oct 28, 2025 09:00 CET Report this content
New, additional funding awarded to Recipharm to advance AI-enabled manufacturing technologies for glob... |
| 15.10.2025 | Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON | Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON
Wed, Oct 15, 2025 10:25 CET Report this content
Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression to phase 2 clinic... |
| 13.10.2025 | Recipharm inaugurates state-of-the-art parenteral development and sterility laboratories | Recipharm inaugurates state-of-the-art parenteral development and sterility laboratories
Mon, Oct 13, 2025 10:44 CET Report this content
Expanded capabilities: new facilities strengthen Recipharm’s global development and testing services.
A... |
| 08.10.2025 | Recipharm announces Centre of Excellence for Advanced Biologics Analytical Services | Recipharm announces Centre of Excellence for Advanced Biologics Analytical Services
Wed, Oct 08, 2025 13:03 CET Report this content
Lab staffed with expert biochemists and biologists
Centre of Excellence provides customers with faster, more... |
| 08.09.2025 | Recipharm partners with NeuroSense Therapeutics to advance ALS therapy PrimeC toward Phase 3 trials | Recipharm partners with NeuroSense Therapeutics to advance ALS therapy PrimeC toward Phase 3 trials
Mon, Sep 08, 2025 10:00 CET Report this content
Recipharm showcases advanced formulation expertise in complex fixed-dose development
Overcam... |
| 21.07.2025 | OncoZenge Appoints Meribel Pharma as CDMO for BupiZenge™ Phase 3 Project | OncoZenge Appoints Meribel Pharma as CDMO for BupiZenge™ Phase 3 Project
Mon, Jul 21, 2025 09:50 CET Report this content
OncoZenge AB ("OncoZenge" or "the Company") today announced it has engaged Meribel Pharma Solutions... |
| 23.06.2025 | Recipharm strengthens BFS leadership with new development contracts, enabling over 90% API savings | Recipharm strengthens BFS leadership with new development contracts, enabling over 90% API savings
Mon, Jun 23, 2025 10:37 CET Report this content
Recipharm is the only CDMO with Blow-Fill-Seal (BFS) capabilities for both biologics and smal... |
| 19.06.2025 | ReciBioPharm: Pioneering the Future of Biomanufacturing | In the world of biomanufacturing, speed and precision are paramount. ReciBioPharm, a segment of Recipharm, is at the forefront of this revolution. With its innovative Process Analytical Technology (PAT) platform, unveiled at the recent Bio ... |
| 18.06.2025 | ReciBioPharm celebrates strong first half of 2025 with momentum for the future | ReciBioPharm celebrates strong first half of 2025 with momentum for the future
Wed, Jun 18, 2025 10:45 CET Report this content
First half of 2025 positions Recipharm’s advanced biologics business for further success in the remainder of the ... |
| 17.06.2025 | ReciBioPharm unveils ground-breaking, real-time PAT platform at Bio Summit | ReciBioPharm unveils ground-breaking, real-time PAT platform at Bio Summit
Tue, Jun 17, 2025 12:15 CET Report this content
Reduces time in analytical testing and quality control
Enables faster, smarter delivery of medicines through real-tim... |
| 09.06.2025 | University of Oxford and ReciBioPharm expand strategic collaboration in fight against malaria | University of Oxford and ReciBioPharm expand strategic collaboration in fight against malaria
Mon, Jun 09, 2025 10:00 CET Report this content
Expands the collaboration to manufacture two malaria vaccine candidates (R78C and RH5.1) for Phase... |
| 13.05.2025 | Recipharm and PLG announce strategic partnership to accelerate development projects | Recipharm and PLG announce strategic partnership to accelerate development projects
Tue, May 13, 2025 09:00 CET Report this content
Combines Recipharm’s development and manufacturing capabilities with PLG’s product development expertise and... |
| 09.04.2025 | Recipharm exceeds sustainability goals with major milestones | Recipharm exceeds sustainability goals with major milestones
Wed, Apr 09, 2025 09:00 CET Report this content
Exceeded SBTi Scope 2 emissions reduction target (42% by 2030 on a 2021 baseline), six years ahead of schedule (48% reduction in 20... |
| 19.03.2025 | Philanthropy Takes Center Stage: Citi Private Bank's New Solutions in Asia | In the heart of Asia, a philanthropic revolution is brewing. Citi Private Bank has launched new philanthropy advisory solutions aimed at ultra-high net worth clients. This initiative, which kicked off in Singapore, is a response to a growin... |
| 14.03.2025 | Recipharm reports record 2024 revenue and strategic milestones | Recipharm reports record 2024 revenue and strategic milestones
Fri, Mar 14, 2025 10:00 CET Report this content
Record-breaking 2024 revenue: €827 million (+7% YoY), driven by strong growth and strategic execution
Biologics growth: record co... |
| 27.02.2025 | Recipharm further expands product development capabilities with new pilot scale development | Recipharm further expands product development capabilities with new pilot scale development
Thu, Feb 27, 2025 09:00 CET Report this content
Complements existing product development and manufacturing capabilities in oral solid, sterile fill ... |
| 05.02.2025 | Recipharm expands aseptic filling capabilities for process development, pilot scale and clinical supply | Recipharm expands aseptic filling capabilities for process development, pilot scale and clinical supply
Wed, Feb 05, 2025 10:00 CET Report this content
GMP aseptic filling under isolator conditions, for process development, pilot scale and ... |
| 22.01.2025 | Spektus Pharma and Recipharm Announce Strategic Partnership to Develop and Supply CNS Medicines Using Flexitab™ Oral Drug Delivery Platform | Spektus Pharma and Recipharm Announce Strategic Partnership to Develop and Supply CNS Medicines Using Flexitab™ Oral Drug Delivery Platform
Wed, Jan 22, 2025 10:00 CET Report this content
Montreal – Spektus Pharma, an innovator in value add... |
| 14.01.2025 | Advancing Healthcare: The New Wave of Innovation in RNA and Neuroscience | In the world of healthcare, innovation is the lifeblood. Two recent developments showcase this truth: ReciBioPharm's grant for RNA manufacturing and BrainSightAI's funding for neuroinformatics. Both are pushing boundaries, aiming to make he... |
| 13.01.2025 | ReciBioPharm secures a significant grant to advance RNA manufacturing | ReciBioPharm secures a significant grant to advance RNA manufacturing
Mon, Jan 13, 2025 11:00 CET Report this content
3-year grant received from the Bill & Melinda Gates Foundation to enhance RNA production technologies
Grant enables gl... |
| 19.11.2024 | Recipharm’s full range Oral Solid Dosage (OSD) capabilities meet growing industry demands | Recipharm’s full range Oral Solid Dosage (OSD) capabilities meet growing industry demands
Tue, Nov 19, 2024 09:00 CET Report this content
Full range OSD development and manufacturing capabilities from orphan drugs to blockbusters
High poten... |
| 04.10.2024 | A New Era in Pharmaceutical Manufacturing: Recipharm and Exela Join Forces | In the fast-paced world of pharmaceuticals, alliances can be game-changers. Recently, Recipharm and Exela Pharma Sciences announced a strategic partnership that promises to reshape sterile manufacturing in the United States. This collaborat... |
| 03.10.2024 | Recipharm strengthens pharmaceutical development capabilities with strategic investments | Recipharm strengthens pharmaceutical development capabilities with strategic investments
Thu, Oct 03, 2024 09:00 CET Report this content
New investments include expanded capabilities in Oral Solid Dosage (OSD), Sterile Fill & Finish (SF... |
| 01.10.2024 | Recipharm and Exela announce exclusive strategic alliance | Recipharm and Exela announce exclusive strategic alliance
Tue, Oct 01, 2024 09:00 CET Report this content
Sterile manufacturing capability in the US with over 100 million readily-available units (including vials and Pre-Filled Syringes – PF... |
| 16.09.2024 | Recipharm’s investment enhances efficiency and speed for customers and patients | Recipharm’s investment enhances efficiency and speed for customers and patients
Mon, Sep 16, 2024 09:00 CET Report this content
Three new GMP Pilot Scale suites for blending, tableting and hard capsule filling
Complements existing GMP pilot... |
| 04.09.2024 | Introducing ReciPredict: Revolutionising Drug Product Development and Manufacturing | Introducing ReciPredict: Revolutionising Drug Product Development and Manufacturing
Wed, Sep 04, 2024 11:45 CET Report this content
30-70% API consumption reduction during development and scale up
Reduce time to clinical stage by up to 6 mo... |
| 20.06.2024 | Azzur Group Appoints Nick Mazzucca as Vice President of Sales and Marketing | HATBORO, Pa., June 20, 2024 /PRNewswire/ -- Azzur Group, a comprehensive solutions provider for life science innovators in the regulated space, is excited to announce the appointment of Nick Mazzucca as Vice President of Sales and Marketing... |
| 26.03.2024 | Recipharm attains major sustainability milestones | Recipharm attains major sustainability milestones
Tue, Mar 26, 2024 09:00 CET Report this content
Approval of ambitious Greenhouse Gas emission reduction targets by SBTi
Commitment to renewable electricity sourcing to 100.0% by 2024 and to ... |
| 13.03.2024 | $69.7 Billion Oral Solid Dosage Contract Manufacturing Market Assessment 2024-2034 Featuring Lonza Group, Catalent, Recipharm | - |
| 13.03.2024 | ReciBioPharm and GeneVentiv Therapeutics partner to advance first AAV-based gene therapy for haemophilia patients with inhibitors | ReciBioPharm and GeneVentiv Therapeutics partner to advance first AAV-based gene therapy for haemophilia patients with inhibitors
Wed, Mar 13, 2024 10:00 CET Report this content
ReciBioPharm, the advanced and emerging therapies business uni... |
| 13.03.2024 | Global Oral Solid Dosage Contract Manufacturing Market 2024-2030: Regional Trends for Tablets, Capsules, Powders, and Granules | - |
| 23.01.2024 | Are Swedish Biotech Startups Revolutionising Pharmaceutical Manufacturing? | Key Takeaways:
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) based in Sweden.
The company is redefining the pharmaceutical manufacturing industry with its innovative solutions.
Despite being in operation ... |
| 23.01.2024 | Recipharm, Medspray, and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology | Recipharm, Medspray, and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology
Tue, Jan 23, 2024 14:00 CET Report this content
Partnership will help bring breakthroug... |
| 19.12.2023 | Recipharm Harmonizes its Global Quality Operations with Veeva Vault Quality | Leading CDMO adopts Veeva Vault QMS, Vault QualityDocs, and Vault Training to standardize quality processes and manage GxP content across its organization
Veeva Systems announced that Recipharm, a global contract development and manufacturi... |
| 19.12.2023 | Recipharm harmonizes its global quality operations with Veeva Vault Quality | Recipharm harmonizes its global quality operations with Veeva Vault Quality
Tue, Dec 19, 2023 13:05 CET Report this content
Leading CDMO adopts Veeva Vault QMS, Vault QualityDocs, and Vault Training to standardize quality processes and mana... |
| 11.12.2023 | ReciBioPharm partners with Acuitas Therapeutics to provide rapid technology transfers and CGMP manufacture of Acuitas’ LNP formulations | ReciBioPharm partners with Acuitas Therapeutics to provide rapid technology transfers and CGMP manufacture of Acuitas’ LNP formulations
Mon, Dec 11, 2023 10:00 CET Report this content
ReciBioPharm, the advanced and emerging therapies busine... |
| 05.12.2023 | Recipharm announces collaboration with Oz-UK to accelerate the development of low global warming potential pMDIs utilising HFA-152a propellant | Recipharm announces collaboration with Oz-UK to accelerate the development of low global warming potential pMDIs utilising HFA-152a propellant
Tue, Dec 05, 2023 09:00 CET Report this content
Simon Gardner appointed to support customers to t... |
| 05.09.2023 | Recipharm partners with Ahead Therapeutics to develop rare autoimmune disease therapy | Recipharm partners with Ahead Therapeutics to develop rare autoimmune disease therapy
Tue, Sep 05, 2023 09:00 CET Report this content
Global contract development and manufacturing organisation (CDMO) Recipharm is partnering with Ahead Thera... |
| 23.08.2023 | Recipharm makes senior appointments as transition to low global warming potential propellants in pressurised Metered Dose Inhalers gains pace | Recipharm makes senior appointments as transition to low global warming potential propellants in pressurised Metered Dose Inhalers gains pace
Wed, Aug 23, 2023 09:00 CET Report this content
Global contract development and manufacturing orga... |
| 17.08.2023 | Recipharm and Honeywell to speed development of inhalers with a near-zero global warming potential propellant | Recipharm and Honeywell to speed development of inhalers with a near-zero global warming potential propellant
Thu, Aug 17, 2023 12:00 CET Report this content
Partnership will reduce environmental footprint of pressurized metered dose inhale... |
| 11.07.2023 | Recipharm’s new analytical lab brings impressive testing capabilities to global markets | Recipharm’s new analytical lab brings impressive testing capabilities to global markets
Tue, Jul 11, 2023 10:00 CET Report this content
Global contract development and manufacturing organisation (CDMO) Recipharm has opened a new analytical ... |
| 11.05.2023 | NewBiologix launches with $50M to make gene therapies more viable | |
| 02.05.2023 | FDA approves the manufacture of new microbiome-based therapeutic VOWST™ at Recipharm site | FDA approves the manufacture of new microbiome-based therapeutic VOWST™ at Recipharm site
Tue, May 02, 2023 11:30 CET Report this content
Recipharm, a global contract development and manufacturing organization (CDMO), has announced today th... |
| 28.04.2023 | Arranta Bio, a Recipharm company, signs contract with MIT to develop rapid manufacturing of mRNA therapeutics | Arranta Bio, a Recipharm company, signs contract with MIT to develop rapid manufacturing of mRNA therapeutics
Fri, Apr 28, 2023 14:30 CET Report this content
Contract with MIT follows the largest award from FDA’s Center for Biologics Evalua... |
| 04.04.2023 | Recipharm bolsters senior leadership team with appointment of Joaquim Mascaro as Chief Financial Officer | Recipharm bolsters senior leadership team with appointment of Joaquim Mascaro as Chief Financial Officer
Tue, Apr 04, 2023 08:00 CET Report this content
Global contract development and manufacturing organisation (CDMO) Recipharm, has announ... |
| 16.03.2023 | Stevanato Group collaborates with Recipharm to develop and manufacture pre-fillable syringes for use in a new soft mist inhaler for the inhalation of sensitive biological products | Stevanato Group collaborates with Recipharm to develop and manufacture pre-fillable syringes for use in a new soft mist inhaler for the inhalation of sensitive biological products
Thu, Mar 16, 2023 14:00 CET Report this content
The new stra... |
| 16.03.2023 | Stevanato Group collaborates with Resyca® to develop and manufacture pre-fillable syringes for use in a new soft mist inhaler for the inhalation of sensitive biological products | Stevanato Group collaborates with Resyca® to develop and manufacture pre-fillable syringes for use in a new soft mist inhaler for the inhalation of sensitive biological products
Thu, Mar 16, 2023 14:00 CET Report this content
The new strate... |
| 09.03.2023 | Recipharm’s Arranta Bio expands RNA process development capacity by 50 per cent to meet increased customer demand | Recipharm’s Arranta Bio expands RNA process development capacity by 50 per cent to meet increased customer demand
Thu, Mar 09, 2023 09:00 CET Report this content
Arranta Bio, a Recipharm company and leading contract development and manufact... |
| 05.12.2022 | Recipharm announces extension of commercial manufacturing to support RedHill Biopharma’s Talicia® to 2026 | Recipharm announces extension of commercial manufacturing to support RedHill Biopharma’s Talicia® to 2026
Mon, Dec 05, 2022 10:00 CET Report this content
Global contract development and manufacturing organisation (CDMO) Recipharm, today ann... |
| 30.11.2022 | Recipharm invests in its single dose nasal platform capabilities | Recipharm invests in its single dose nasal platform capabilities
Wed, Nov 30, 2022 10:00 CET Report this content
Recipharm, a global contract development and manufacturing organisation (CDMO), has announced that it is expanding its capabili... |
| 14.07.2022 | Transpire Bio announces agreement with Recipharm for the development of an inhaled medicine | Transpire Bio announces agreement with Recipharm for the development of an inhaled medicine
Thu, Jul 14, 2022 15:30 CET Report this content
Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics... |
| 29.04.2022 | Recipharm offers services to enable switch to next generation pMDI propellants | Recipharm offers services to enable switch to next generation pMDI propellants
Fri, Apr 29, 2022 08:00 CET Report this content
Global contract development and manufacturing organisation (CDMO) Recipharm, today announces that it is expanding... |
| 11.04.2022 | Recipharm completes US biologics acquisitions | Recipharm completes US biologics acquisitions
Mon, Apr 11, 2022 07:00 CET Report this content
Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announces the closing of its acquisitions of advance... |
| 10.03.2022 | Recipharm pledges support to conflict victims | Recipharm pledges support to conflict victims
Thu, Mar 10, 2022 08:00 CET Report this content
Recipharm, the global contract development and manufacturing organisation (CDMO), has today announced its commitment to helping victims of the con... |
| 24.02.2022 | On a roll, Recipharm wraps up its second and third CDMO acquisitions this month | Recipharm is ending the month of February the same way it started: with an acquisition. Two of them, to be precise.
The Swedish company will bolster its CDMO operations with the acquisitions of Arranta Bio and Vibalogics. The two deals will... |
| 23.02.2022 | Recipharm invests in new high-speed filling line to meet demand for aseptic products | Recipharm invests in new high-speed filling line to meet demand for aseptic products
Wed, Feb 23, 2022 13:00 CET Report this content
Global contract development and manufacturing organisation (CDMO), Recipharm, is investing to expand its st... |
| 18.02.2022 | Recipharm acquires Arranta Bio, a CDMO leader in advanced therapy medicinal products (ATMPs), to expand its biologics offering in the US | Recipharm acquires Arranta Bio, a CDMO leader in advanced therapy medicinal products (ATMPs), to expand its biologics offering in the US
Fri, Feb 18, 2022 08:00 CET Report this content
Recipharm, a leading global contract development and ma... |
| 18.02.2022 | Recipharm expands its advanced therapy medicinal products (ATMPs) offering into Virotherapies with the acquisition of Vibalogics | Recipharm expands its advanced therapy medicinal products (ATMPs) offering into Virotherapies with the acquisition of Vibalogics
Fri, Feb 18, 2022 08:00 CET Report this content
Recipharm, a global contract development and manufacturing orga... |
| 01.02.2022 | Recipharm acquires GenIbet to bolster Biologics offering | Recipharm acquires GenIbet to bolster Biologics offering
Tue, Feb 01, 2022 11:45 CET Report this content
Global contract development and manufacturing organisation (CDMO), Recipharm, has today announced the acquisition of GenIbet, a Portugu... |
| 28.01.2022 | Construction works launch at new fill finish facility in Morocco | Construction works launch at new fill finish facility in Morocco Fri, Jan 28, 2022 10:00 CET
Global contract development and manufacturing organisation (CDMO) Recipharm, in charge of shaping the new entity SENSYO Pharmatech, has attended a ... |
| 27.01.2022 | Recipharm secures vaccine manufacturing deal | Recipharm secures vaccine manufacturing deal Thu, Jan 27, 2022 09:00 CET
Global contract development and manufacturing organization (CDMO), Recipharm, has inked a deal with a top 10 big pharma company to support vaccine manufacturing from i... |
| 11.01.2022 | Low-profile Shanghai-based CDMO secures high profile investors for 9-digit Series C | In a bid to expand R&D and manufacturing capabilities, Shanghai-based ZhenGe Biotech netted a $100 million Series C Tuesday.
With offices in Shanghai and the US, the transpacific CDMO garnered the support of Goldma... |
| 11.01.2022 | Recall report: Another month, another issue with NDMA | It’s been six months since the last incident, but 2021 ended with the tally resetting back to “zero days.”
Viona Pharmaceuticals is recalling 33 lots of metformin hydrochloride after finding traces of NDMA, a known proba... |
| 11.01.2022 | After a year of big investments, Recipharm sells off assets in Europe | Recipharm is having a yard sale to start the new year.
The company announced a pair of deals Monday, as the Sweedish biotech sold its Fontaine-lès-Dijon, France manufacturing site to a newly-established CDMO Astrea Pharma... |
| 11.01.2022 | Korean conglomerate SK takes out stake in cell and gene therapy CDMO with plans for a major hiring spree outside Philly | A Pennsylvania CDMO specializing in cell and gene therapy manufacturing is receiving a big influx of cash from a South Korean drugmaker — and it has plans for a major hiring spree.
SK, the holding company of SK bio... |
| 10.01.2022 | Pharmaron acquires commercial API manufacturing facility in the United Kingdom from Recipharm | Pharmaron acquires commercial API manufacturing facility in the United Kingdom from Recipharm Mon, Jan 10, 2022 12:05 CET
Continues to strengthen the global chemistry and manufacturing capabilities and capacities
Pharmaron Beijing Co., Limi... |
| 10.01.2022 | Recipharm announces sale of Fontaine-lès-Dijon site to Astrea | Recipharm announces sale of Fontaine-lès-Dijon site to Astrea Mon, Jan 10, 2022 10:15 CET
Recipharm today announces the sale to Astrea Pharma, the newly established CDMO provider focused on small molecule oral solid and aseptic dosages, of ... |
| 24.09.2021 | First customer boards Recipharm’s soft mist inhaler technology platform | First customer boards Recipharm’s soft mist inhaler technology platform Fri, Sep 24, 2021 11:00 CET
Resyca, Recipharm’s joint venture with Medspray, has boarded its first pharmaceutical customer on the soft mist inhaler (SMI) platform. An a... |
| 24.08.2021 | Recipharm launches new laboratory to expand analytical services offering | Recipharm launches new laboratory to expand analytical services offering Tue, Aug 24, 2021 11:00 CET
Global contract development and manufacturing organisation (CDMO), Recipharm, has announced the completion of a new analytical laboratory a... |
| 15.07.2021 | Recipharm invests in fill finish capacity | Recipharm invests in fill finish capacity Thu, Jul 15, 2021 13:00 CET
Global contract development and manufacturing organisation (CDMO), Recipharm, has announced investment into a new facility in Uttarakhand, India which will see its fill f... |
| 05.01.2021 | Moderna inks deal for overseas Covid-19 vaccine finishing work as European approval hangs in balance | Despite a lack of formal approval from the European Medicines Agency, Moderna is moving to nail down production capacity for the doses of its mRNA-based Covid-19 vaccine that will be jabbed into arms outside of the U.S.
... |
| 14.12.2020 | EQT : IX, through Roar BidCo AB, announces a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB (publ) and SEK 1,427,010 in cash per Convertible Bond | EQT IX[1 ]("EQT IX"), through Roar BidCo AB[2] ("Roar BidCo"), hereby announces a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds (the "Convertible Bonds") ("Holders ... |
| 14.12.2020 | EQT AB (PUBL)
EQT : IX, through Roar BidCo AB, announces a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB (publ) and SEK 1,427,010 in cash per Convertible Bond | EQT IX[1 ]("EQT IX"), through Roar BidCo AB[2] ("Roar BidCo"), hereby announces a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds (the "Convertible Bonds") ("Holders ... |
| 14.06.2018 | Sanofi sells manufacturing site to Recipharm; Aptose buys rights to sell CrystalGenomics' cancer drug in China | → Sanofi is selling off its contract respiratory drug manufacturing site in the UK to Recipharm, which is picking up manufacturing capacity as well as new clients in the $60 million deal. The plant’s 450 staffers will s... |
